What is Iovance Biotherapeutics, Inc.'s business segments — D&A?

Iovance Biotherapeutics, Inc. (IOVA) reported business segments — D&A of $8.54M in Q1 2026.

How has Iovance Biotherapeutics, Inc.'s business segments — D&A changed year-over-year?

Iovance Biotherapeutics, Inc.'s business segments — D&A increased by 5.9% year-over-year, from $8.07M to $8.54M.

What does business segments — D&A mean?

This reflects the systematic allocation of the cost of tangible and intangible assets over their useful lives. It provides insight into the capital intensity of the business and the ongoing investment required to maintain operational infrastructure.

Iovance Biotherapeutics, Inc. IOVA Business Segments — D&A

Similar metrics at other companies

RGTISingle Reportable — D&A

$2.62M+43.0%

SRRKSingle Reportable — D&A

$335K-14.8%

QURESingle Reportable — D&A

$2.96M-34.7%

PAYOSingle Reportable — D&A

$18.92M+31.5%

OCULSingle Reportable — D&A

$1.26M+28.4%

MCRISingle Reportable — D&A

$10.47M-20.8%

Other financials

Income statement

See full

Revenue$71.4M+44.8%

Gross profit$28.9M+338%

Operating income-$81.0M+33.1%

Net income-$79.0M+32.0%

EPS (diluted)-$0.19+47.2%

Balance sheet

See full

Cash & equivalents$196.5M+14.5%

Total debt$46.8M-11.3%

Total equity$721.8M-6.0%

Total assets$925.7M-4.2%

Cash flow

See full

Operating cash flow-$72.1M+30.5%

CapEx$6.6M+6.4%

Free cash flow-$78.7M+28.4%

Valuation

See full

Market cap$1.98B+32.4%

Enterprise value$1.83B+33.2%

P/S6.9×-0.1×

Profitability

See full

Gross margin36.7%+4.1pp

Operating margin-127.2%-31.0pp

Net margin-123.9%-28.4pp

FCF margin-106.8%-27.5pp

Returns & leverage

See full

Return on equity-47.5%-3.7pp

Debt / equity0.1×0.0×

Current ratio3.6×-0.6×

Where this comes from

Reported directly by Iovance Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DepreciationAndAmortization.

The official record: Iovance Biotherapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Iovance Biotherapeutics, Inc.'s business segments — d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Iovance Biotherapeutics, Inc.'s business segments — D&A?: Iovance Biotherapeutics, Inc. (IOVA) reported business segments — D&A of $8.54M in Q1 2026.
How has Iovance Biotherapeutics, Inc.'s business segments — D&A changed year-over-year?: Iovance Biotherapeutics, Inc.'s business segments — D&A increased by 5.9% year-over-year, from $8.07M to $8.54M.
What does business segments — D&A mean?: This reflects the systematic allocation of the cost of tangible and intangible assets over their useful lives. It provides insight into the capital intensity of the business and the ongoing investment required to maintain operational infrastructure.